KP2M LTD
Company number 09002485 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: B-
Explanation: The company shows robust liquidity and a strong balance sheet with low debt, but a history of mounting accumulated losses and reliance on equity injections prevents a higher grade. The recent substantial improvement in working capital and cash position is encouraging, yet the persistent negative retained earnings signal that the business has not yet reached sustainable profitability.
Key Vital Signs
| Metric | 2025 | 2024 | Interpretation |
|---|---|---|---|
| Current Ratio | 2.76 | 0.63 | Healthy ‒ Current assets comfortably cover short-term obligations. A year ago the business was technically illiquid; now it has a strong safety buffer. |
| Quick Ratio | 1.74 | 0.34 | Strong ‒ Even without selling stock, the company can meet nearly twice its current liabilities, indicating ample short-term financial flexibility. |
| Debt-to-Equity | 0.20 | 1.61 | Very low gearing ‒ The business relies almost entirely on equity, leaving little risk from fixed interest charges. The sharp drop from 2024 reflects a major paydown of creditors. |
| Cash Position | £601,633 | £95,756 | Healthy and much improved ‒ Cash has multiplied over sixfold, providing a cushion for operations and investment. |
| Net Assets | £2,368,998 | £1,047,463 | Recovering ‒ After a two‑year decline, net assets more than doubled in 2025, driven by a substantial share‑premium injection. |
| Profit & Loss Reserve | (£8,441,069) | (£6,657,840) | Concerning ‒ Cumulative losses have deepened, meaning the business has not yet generated profits to cover its costs; each year adds to the deficit. |
Additional Observations: - Working capital: moved from a deficit of £623,257 in 2024 to a surplus of £813,205 in 2025 – a vital‑sign turnaround. - Intangible assets (patents) make up 63% of fixed assets; amortisation charged is £122,968 per year. - Equity injection: The company raised £3.1m through a new share issue in 2025, which accounts for most of the improvement in net assets and cash.
Diagnosis
KP2M Ltd presents as a growth‑stage business with strong liquidity but chronic profitability issues. The patient’s “vital signs” – current ratio, quick ratio, low debt – are healthy, and the recent cash infusion has stabilised what a year ago looked like a distressed working‑capital condition. However, the persistent and growing negative profit‑and‑loss reserve is the equivalent of a recurring fever: the core operations are not yet generating profit, and accumulated losses now exceed £8.4m. The company is being kept afloat by repeated equity injections from its shareholders, and its tangible net worth (excluding the share premium and intangible assets) is actually negative when viewed through the lens of retained earnings.
The business model appears to involve heavy investment in development and patents (intangible assets), which is typical for a technology‑oriented manufacturer. The increase in headcount from 21 to 27 employees suggests continued expansion. Yet without a profitable trading record, the company remains dependent on external funding and has not demonstrated the ability to self‑finance.
Recommendations
- Accelerate path to profitability – Focus on converting the patented technology and growing order book into positive bottom‑line results. A detailed profitability analysis (e.g., gross margin, operating expenses) would help identify cost drivers and pricing opportunities.
- Manage intangible asset amortisation – With patents amortising over 20 years, ensure that the carrying value of £1.5m is regularly tested for impairment. Any delay in commercialising the related products could lead to impairment charges that further strain reserves.
- Monitor cash burn – The substantial cash balance is a buffer, but the company’s operating cash flow should be tracked carefully. If losses continue, the current cash runway (even at £602k) may prove short unless further equity is raised.
- Strengthen working capital discipline – The dramatic paydown of creditors is commendable. Maintain tight control over trade debtors and stock to prevent a reversal of the improved liquidity position.
- Diversify funding sources – While equity injections are available, the company should explore debt financing or revenue‑based financing to reduce dilution and signal confidence to investors.
KP2M Ltd has stabilised its short‑term financial health through a major equity raise and debt reduction, achieving strong liquidity and a very low debt ratio. However, the business continues to operate at a loss and carries a large accumulated deficit, indicating it has not yet reached sustainable profitability. The outlook is positive if the company can translate its investment in patents and growing workforce into profitable sales; without that, it remains dependent on further external funding.